Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer - Wikidata - wikimedia - TriplyDB

Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer

Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer

http://www.wikidata.org/entity/Q35460703

about

Immunological Landscape and Clinical Management of Rectal Cancer MTHFR C677T Polymorphism is Associated with Tumor Response to Preoperative Chemoradiotherapy: A Result Based on Previous Reports Genetic and epigenetic traits as biomarkers in colorectal cancer Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer TP53 and let-7a micro-RNA regulate K-Ras activity in HCT116 colorectal cancer cells Comparative analysis of radiosensitizers for K-RAS mutant rectal cancers Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies.Can an IL13 -1112 C/T (rs1800925) polymorphism predict responsiveness to neoadjuvant chemoradiotherapy and survival of Chinese Han patients with locally advanced rectal cancer?KRAS Mutation Status Is Not a Predictor for Tumor Response and Survival in Rectal Cancer Patients Who Received Preoperative Radiotherapy With 5-Fluoropyrimidine Followed by Curative Surgery.Distribution of residual cancer cells in the bowel wall after neoadjuvant chemoradiation in patients with rectal cancer.Intra-tumor genetic heterogeneity in rectal cancer Comparative analysis of lymph node metastases in patients with ypT0-2 rectal cancers after neoadjuvant chemoradiotherapy.An 80-gene set to predict response to preoperative chemoradiotherapy for rectal cancer by principle component analysis The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers.Mismatch Repair Gene Expression as a Predictor of Tumor Responses in Patients With Rectal Cancer Treated With Preoperative Chemoradiation.Pathological Assessment of Rectal Cancer after Neoadjuvant Chemoradiotherapy: Distribution of Residual Cancer Cells and Accuracy of Biopsy.Is Pathologic Near-Total Regression an Appropriate Indicator of a Good Response to Preoperative Chemoradiotherapy Based on Oncologic Outcome of Disease?Predictive and Prognostic Molecular Biomarkers for Response to Neoadjuvant Chemoradiation in Rectal Cancer.Effect of Neoadjuvant Chemoradiotherapy on Locally Advanced Rectal Mucinous Adenocarcinoma: A Propensity Score-Matched Study.Minimal access surgery for rectal cancer: an update.Comprehensive molecular exploration identified promoter DNA methylation of the CRBP1 gene as a determinant of radiation sensitivity in rectal cancer.Germ line polymorphisms as predictive markers for pre-surgical radiochemotherapy in locally advanced rectal cancer: a 5-year literature update and critical review.Germline and somatic genetic predictors of pathological response in neoadjuvant settings of rectal and esophageal cancers: systematic review and meta-analysis.Predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review.Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples.Progress in rectal cancer treatment.KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.Mutations in specific codons of the KRAS oncogene are associated with variable resistance to neoadjuvant chemoradiation therapy in patients with rectal adenocarcinoma Modern Treatment of Rectal Cancer Closes the Gap Between Common Adenocarcinoma and Mucinous Carcinoma.Predictive clinical model of tumor response after chemoradiation in rectal cancer.Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.Cetuximab in preoperative treatment of rectal cancer - term outcome of the XERT trial.Low Mmp 9 and VEGF levels predict good oncologic outcome in mid and low rectal cancer patients with neoadjuvant chemoradiation.High Ran level is correlated with poor prognosis in patients with colorectal cancer.Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes.KRAS mutations and rectal cancer response to chemoradiation: are we closer to personalization of therapy?Molecular Biology: Are We Getting Any Closer to Providing Clinically Useful Information?Predicting complete response to neoadjuvant CRT for distal rectal cancer using sequential PET/CT imaging.

P2860

Q26768531-5DC781C3-29C0-458D-B79A-7D33D18C8AED Q26784493-6CF78A6F-5102-4E88-9D60-D566C2FC1CF5 Q27016019-ACF8E4F3-2CF1-4392-9236-A61199CF3415 Q28392548-5B9EC33F-97BF-4A45-ABE4-DDE53681F5FC Q34926012-B4ADA4D3-ECDE-42A7-BB30-3F70BD54B49C Q35070685-AFB7AC99-148F-4E6E-883F-6BFB9D2D285C Q35183160-30E7DA28-6391-4CBC-B2E3-C709216E982A Q35832569-A2F7CEF9-9A34-4652-A282-4D2CC856D308 Q35859128-4981653A-AFBA-4153-B719-FDED16DD46BF Q36014263-28C326AD-29AE-42E1-8851-D4777AFFC34F Q36194689-EAAA7FE6-5336-4A6C-8137-53757464FE2E Q36358764-748A4F4B-E863-47F9-8585-51FB8EB24EB9 Q36414682-A609CEBC-02AF-4819-A79F-21DAFB60692B Q36540452-DAC3CEF8-909B-4B87-9B8E-A39B2F8D02A2 Q36824711-236CD2E3-37D7-476B-920B-62E0FACCA571 Q37015715-003276A3-0E2F-4E5E-8977-5C318FF25FF7 Q37205031-22249012-BD76-48F9-9B9A-8883437B208B Q37323833-C1050AF8-E913-4B2D-A828-259BA3873E73 Q37328335-EDFB0085-1366-4BB9-86F0-90BD6B6FD613 Q37729169-9B7E51BE-E6AD-410B-925A-F808DDCA5AEB Q37733511-C8F2FAC3-0F87-4B2D-9D29-BE302769C069 Q38160142-2407E4E1-DB85-45E1-BC49-08C71DFF7F4F Q38288716-A18455BC-4319-45A0-A2EA-1528BE10D20D Q38367771-8B63DD35-4A71-4189-9F77-88A0B636EEA6 Q38539917-5A7C2BFE-402F-478D-B0FE-8FD9EEA01164 Q38623990-0D4BD213-5B87-4B58-A928-FB18667C9195 Q39307013-69B28184-5766-49BC-AFCC-E22BE5C44DF1 Q39554319-65C9FF2C-EBC8-4DAF-918A-1FF113DF037F Q39884524-760A3FB2-3FFC-4C4B-A429-E023A3E251F4 Q41614877-507DC780-5432-4306-9AE2-211213857E6F Q41616758-A0F34679-1E4B-4700-B941-8A46928526D8 Q41708765-B02F2907-2588-492F-B1FB-E8D7B3FDE2EF Q42160986-DC9FA114-62B9-4FFA-9015-5BD10DFA1C2B Q42423159-57E1541B-C783-408B-8BC4-678429173CA3 Q42669180-06088907-ABD7-40C5-ACCF-152B0780C75E Q46559488-982FA7E2-552E-4F69-B610-4848D99DBB58 Q46582003-70B4B709-288C-4731-80F9-35E1C58A173E Q47988485-A12AB734-DC9B-46A4-8D1B-B08B0EF84DA7 Q49564034-F20B249A-73C7-4732-89EE-74C5842B2E1E Q53079996-FC988F7D-6964-4E50-A5A7-8443157CDCA9

P2860

Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer

http://www.wikidata.org/entity/Q35460703

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Identification of a biomarker ...... ation therapy in rectal cancer

@ast

Identification of a biomarker ...... ation therapy in rectal cancer

@en

type

label

Identification of a biomarker ...... ation therapy in rectal cancer

@ast

Identification of a biomarker ...... ation therapy in rectal cancer

@en

prefLabel

Identification of a biomarker ...... ation therapy in rectal cancer

@ast

Identification of a biomarker ...... ation therapy in rectal cancer

@en

P1433

Q35460703-65586FE4-B9AC-441B-932B-23D3DAEF18D3

P1476

Q35460703-60C83029-9355-4C76-B726-7A561B23106C

P2093

Q35460703-236B43F3-AF99-4C5D-8CDD-CD44C1231487

Q35460703-52660EB7-D2E3-413A-AD05-E5F324CB9CCA

Q35460703-63BBFE98-ED0E-452F-8E83-F32C91B9BC10

Q35460703-66151A68-A453-486B-8F52-C2D499B4868F

Q35460703-73BD7756-6490-431C-A7BB-FEE9A420803A

Q35460703-8CF67A87-CC84-49A0-87EA-0F9658B204DD

Q35460703-954E5C47-103C-40F8-BA3A-7FCBA3597AD1

Q35460703-C88F42DE-6D96-403C-977F-5BE81F463E0B

P2860

Q35460703-001979D4-92BD-46A1-AC57-AA228AC53172

Q35460703-0CB17E87-30A9-4754-A2CB-A518D61751B8

Q35460703-0D249762-4B50-4A1B-A928-3E92756FD736

Q35460703-0D2EF322-C235-4527-86D6-A78C922427FD

Q35460703-116D47F4-7C57-4A92-BBBB-3B01BAF068CF

Q35460703-13E6D33C-C487-4D41-9FEA-507281AC8943

Q35460703-1E845D60-42A7-4DD3-9E61-0D1B3A84DD91

Q35460703-2732265C-8B8D-4CE9-B8A4-BBCB269760B3

Q35460703-2A72C17B-AE4F-49C6-821C-07FF4855BD0E

Q35460703-2BDAC090-7D23-4F83-822A-301B0C79E5B3

P304

Q35460703-35EC3212-D24D-4642-9BB3-B5200B342C56

P31

Q35460703-565AA298-588E-49BF-BE86-516F69FD4ABD

P356

Q35460703-923E1761-9DBC-4843-BF33-2F31836D291F

P407

Q35460703-33858556-8711-41DD-BB73-6FE2B1F705E1

P433

Q35460703-44721961-4E3C-4C00-B388-D24C0038A0DB

P478

Q35460703-24A5DACE-CCE5-411D-A56B-05FFD2A7E1E3

P577

Q35460703-A9D85041-D766-4AAB-AAB6-08E194A05B63

P698

Q35460703-9DED8EE9-A1A4-48A9-BDC4-5444DD9DBF0C

P921

Q35460703-0DDBEE99-8D9C-48C0-BCFF-1E2E88425CF8

Q35460703-C8048F0C-E439-464D-8D70-D37E74DE98B0

P932

Q35460703-8F2D91E9-8E9A-4E0F-A499-C272E5C4DDEE

P356

SLA.0B013E31822B8CFA

P1433

Annals of Surgery

P1476

Identification of a biomarker ...... ation therapy in rectal cancer

@en

P2093

Carlos Pastor

http://www.w3.org/2001/XMLSchema#string

David D Smith

http://www.w3.org/2001/XMLSchema#string

Jorge Marcet

http://www.w3.org/2001/XMLSchema#string

Julio Garcia-Aguilar

http://www.w3.org/2001/XMLSchema#string

Peter Cataldo

http://www.w3.org/2001/XMLSchema#string

Robert D Madoff

http://www.w3.org/2001/XMLSchema#string

Wenyan Li

http://www.w3.org/2001/XMLSchema#string

Zhenbin Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Alternative cyclin D1 splice forms differentially regulate the DNA damage response

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.

Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients

The mesorectum in rectal cancer surgery—the clue to pelvic recurrence?

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer.

Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy.

Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data.

Abdominoperineal resection for rectal cancer: historic perspective and current issues.

P304

486-92; discussion 492-3

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/SLA.0B013E31822B8CFA

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

254

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21865946

http://www.w3.org/2001/XMLSchema#string

P921

chemoradiotherapy

P932

3202983

http://www.w3.org/2001/XMLSchema#string